Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
54
TAK Quote, Financials, Valuation and Earnings
Last price:
$16.27
Seasonality move
:
-1.64%
Day range:
$15.88 - $16.04
52-week range:
$12.80 - $16.48
Dividend yield:
4.15%
P/E ratio:
202.28x
P/S ratio:
1.72x
P/B ratio:
1.04x
Volume:
3.9M
Avg. volume:
2.8M
1-year change:
23.66%
Market cap:
$50.3B
Revenue:
$30.1B
EPS (TTM):
$0.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.6B | -- | -1.4% | -- | $17.66 |
|
NVS
Novartis AG
|
$13.8B | $2.00 | 3.71% | 14.01% | $137.78 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 2.05% | 43.22% | $28.66 |
|
PTGX
Protagonist Therapeutics, Inc.
|
$34.9M | -$0.56 | -36.31% | -132.23% | $96.33 |
|
SNY
Sanofi
|
$13.1B | $0.85 | -6.06% | 28.6% | $58.08 |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$15.94 | $17.66 | $50.3B | 202.28x | $0.32 | 4.15% | 1.72x |
|
NVS
Novartis AG
|
$145.00 | $137.78 | $278.2B | 19.77x | $3.99 | 2.76% | 5.25x |
|
PFE
Pfizer Inc.
|
$26.10 | $28.66 | $148.4B | 15.21x | $0.43 | 6.59% | 2.37x |
|
PTGX
Protagonist Therapeutics, Inc.
|
$84.79 | $96.33 | $5.3B | 133.89x | $0.00 | 0% | 26.00x |
|
SNY
Sanofi
|
$46.50 | $58.08 | $113.4B | 12.17x | $2.20 | 4.72% | 2.68x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.15 | -- | $466M | -- | $0.00 | 0% | 2.41x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.844 | 68.02% | 0.64x |
|
NVS
Novartis AG
|
41.94% | -0.299 | 12.99% | 0.58x |
|
PFE
Pfizer Inc.
|
39.94% | 0.405 | 42.51% | 0.81x |
|
PTGX
Protagonist Therapeutics, Inc.
|
1.64% | -0.719 | 0.26% | 12.83x |
|
SNY
Sanofi
|
22.66% | -0.271 | -- | 0.81x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.139 | 73.82% | 2.21x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
|
NVS
Novartis AG
|
$10.3B | $4.2B | 19.37% | 33.87% | 30.24% | $5.7B |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
PTGX
Protagonist Therapeutics, Inc.
|
$4.4M | -$46.4M | 7.03% | 7.15% | -985.17% | -$2M |
|
SNY
Sanofi
|
$8.8B | $1.9B | 9.89% | 12.45% | 14.08% | $218.7M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
Takeda Pharmaceutical Co., Ltd. vs. Competitors
-
Which has Higher Returns TAK or NVS?
Novartis AG has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 28.26%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Novartis AG's return on equity of 33.87%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B NVSNovartis AG74.59% $2.02 $76.8B -
What do Analysts Say About TAK or NVS?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.66, signalling upside risk potential of 10.78%. On the other hand Novartis AG has an analysts' consensus of $137.78 which suggests that it could fall by -4.98%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Novartis AG, analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Novartis AG.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 NVSNovartis AG1 5 2 -
Is TAK or NVS More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.019, which suggesting that the stock is 98.068% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.516, suggesting its less volatile than the S&P 500 by 48.422%.
-
Which is a Better Dividend Stock TAK or NVS?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 4.15%. Novartis AG offers a yield of 2.76% to investors and pays a quarterly dividend of $3.99 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios TAK or NVS?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are smaller than Novartis AG quarterly revenues of $13.9B. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Novartis AG's net income of $3.9B. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 202.28x while Novartis AG's PE ratio is 19.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.72x versus 5.25x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.72x 202.28x $7.5B -$79.5M NVSNovartis AG5.25x 19.77x $13.9B $3.9B
-
Which has Higher Returns TAK or PFE?
Pfizer Inc. has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 21.32%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About TAK or PFE?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.66, signalling upside risk potential of 10.78%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 9.8%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Pfizer Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 PFEPfizer Inc.7 15 1 -
Is TAK or PFE More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.019, which suggesting that the stock is 98.068% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.
-
Which is a Better Dividend Stock TAK or PFE?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 4.15%. Pfizer Inc. offers a yield of 6.59% to investors and pays a quarterly dividend of $0.43 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TAK or PFE?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 202.28x while Pfizer Inc.'s PE ratio is 15.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.72x versus 2.37x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.72x 202.28x $7.5B -$79.5M PFEPfizer Inc.2.37x 15.21x $16.7B $3.6B
-
Which has Higher Returns TAK or PTGX?
Protagonist Therapeutics, Inc. has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of -834.87%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Protagonist Therapeutics, Inc.'s return on equity of 7.15%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B PTGXProtagonist Therapeutics, Inc.92.34% -$0.62 $656.2M -
What do Analysts Say About TAK or PTGX?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.66, signalling upside risk potential of 10.78%. On the other hand Protagonist Therapeutics, Inc. has an analysts' consensus of $96.33 which suggests that it could grow by 13.61%. Given that Protagonist Therapeutics, Inc. has higher upside potential than Takeda Pharmaceutical Co., Ltd., analysts believe Protagonist Therapeutics, Inc. is more attractive than Takeda Pharmaceutical Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 PTGXProtagonist Therapeutics, Inc.8 1 0 -
Is TAK or PTGX More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.019, which suggesting that the stock is 98.068% less volatile than S&P 500. In comparison Protagonist Therapeutics, Inc. has a beta of 2.260, suggesting its more volatile than the S&P 500 by 126.048%.
-
Which is a Better Dividend Stock TAK or PTGX?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 4.15%. Protagonist Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Protagonist Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or PTGX?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are larger than Protagonist Therapeutics, Inc. quarterly revenues of $4.7M. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Protagonist Therapeutics, Inc.'s net income of -$39.3M. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 202.28x while Protagonist Therapeutics, Inc.'s PE ratio is 133.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.72x versus 26.00x for Protagonist Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.72x 202.28x $7.5B -$79.5M PTGXProtagonist Therapeutics, Inc.26.00x 133.89x $4.7M -$39.3M
-
Which has Higher Returns TAK or SNY?
Sanofi has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 36.7%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Sanofi's return on equity of 12.45%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B SNYSanofi72.13% $1.83 $106.5B -
What do Analysts Say About TAK or SNY?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.66, signalling upside risk potential of 10.78%. On the other hand Sanofi has an analysts' consensus of $58.08 which suggests that it could grow by 24.91%. Given that Sanofi has higher upside potential than Takeda Pharmaceutical Co., Ltd., analysts believe Sanofi is more attractive than Takeda Pharmaceutical Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 SNYSanofi5 2 0 -
Is TAK or SNY More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.019, which suggesting that the stock is 98.068% less volatile than S&P 500. In comparison Sanofi has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.969%.
-
Which is a Better Dividend Stock TAK or SNY?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 4.15%. Sanofi offers a yield of 4.72% to investors and pays a quarterly dividend of $2.20 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Sanofi pays out 66.53% of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios TAK or SNY?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are smaller than Sanofi quarterly revenues of $12.2B. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Sanofi's net income of $4.5B. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 202.28x while Sanofi's PE ratio is 12.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.72x versus 2.68x for Sanofi. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.72x 202.28x $7.5B -$79.5M SNYSanofi2.68x 12.17x $12.2B $4.5B
-
Which has Higher Returns TAK or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of -24.76%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About TAK or SOLTF?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.66, signalling upside risk potential of 10.78%. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is TAK or SOLTF More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.019, which suggesting that the stock is 98.068% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.011, suggesting its less volatile than the S&P 500 by 98.941%.
-
Which is a Better Dividend Stock TAK or SOLTF?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 4.15%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or SOLTF?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 202.28x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.72x versus 2.41x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.72x 202.28x $7.5B -$79.5M SOLTFNxera Pharma Co., Ltd.2.41x -- $45.8M -$11.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
69
INTC alert for Jan 23
Intel Corp. [INTC] is down 17.6% over the past day.
Buy
51
APGE alert for Jan 23
Apogee Therapeutics, Inc. [APGE] is down 10.71% over the past day.
Buy
70
BNR alert for Jan 23
Burning Rock Biotech Ltd. [BNR] is down 12.45% over the past day.
